Showing 1-10 of 10 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| BimT1D | The University of British Columbia | Jan Dutz | Cures | 01-September-2025 to 31-August-2029 | $2.488.315,00 |
| Image-based phenotyping of stem cell derived islets | The University of British Columbia | Hongshen Ma | Cures | 01-September-2025 to 31-August-2028 | $750.000,00 |
| Subcellular proteomic profiling of human primary and stem cell derived beta cells: A blueprint for making better beta cells | The University of British Columbia | Haoning Cen | Cures | 01-March-2025 to 29-February-2028 | $264.895,00 |
| Modulation of immune cell fate and function by the islet secretome in health and diabetes | The University of British Columbia | Lauar de Brito Monteiro | Cures | 01-March-2024 to 28-February-2027 | $243.055,00 |
| Development of an antigen-specific lipid nanoparticle mRNA therapy for T1D | Integrated Nanotherapeutics, Inc | Chris Tam | Cures | 01-June-2024 to 30-November-2026 | $750.000,00 |
| Using a virtual care platform to deliver peer-led mental health support to rural and remote communities in BC: A randomized wait-list controlled trial of the REACHOUT intervention | The University of British Columbia | Tricia Tang | Improving Lives | 01-September-2022 to 31-December-2026 | $402.429,50 |
| Clinical Phase II/III Trial to treat type 1 diabetes (UST1D2) | The University of British Columbia | Jan Dutz | Cures | 01-November-2020 to 31-December-2027 | $538.854,00 |
| Implementing a virtual care platform to improve mental health for type 1 diabetes in rural and remote regions of Interior British Columbia | The University of British Columbia | Tricia Tang | Improving Lives | 01-April-2020 to 30-January-2026 | $395.552,60 |
| Identification of islet macrophage-derived factors mediating human beta cell regeneration | The University of British Columbia | C. Bruce Verchere | Cures | 01-July-2021 to 31-March-2025 | $299.860,00 |
| Harmonizing biomarkers in clinical trials of ustekinumab | The University of British Columbia | Megan Levings | Cures | 01-July-2018 to 30-June-2027 | $660.059,94 |